🩸🚀 New Insights in Liquid Biopsy! 🧬 The ISLB has just published a perspective article about Minimal requirement for ctDNA analysis. 🔗 Read the full article here www.journalofliquidbiopsy.com/article/S295...

International Society of Liquid Biopsy (ISLB) perspective on minimal requirements for ctDNA testing in solid tumors

Circulating tumor DNA (ctDNA) testing has transformed precision oncology by enabling the non-invasive detection of actionable mutations. To facilitate broader clinical adoption and improve testing acc...

journalofliquidbiopsy.com

🚨Excited to represent the @islb.info at #ASCO25! Swing by our booth, we’re ready to talk about #LiquidBiopsy and opportunities! Got questions about the society? We’ve got answers. Come to connect!🩸 @ascocancer.bsky.social @christianrolfo.bsky.social @rolfolab.bsky.social

#TME in #NSCLC shapes therapy resistance and progression - a tumor can have two immune niches: rich and poor - more than immune cells: CAFs, TAMs, DCs, T, NK.. - patient-specific determinants modulate the TME 🔍emerging technologies www.nature.com/articles/s41...

Promising signals from the ALEK-B ph 2 trial: combining alectinib w bevacizumab achieved 97.1% 12-mo PFS & median PFS of 39.6 months in ALK+ #NSCLC. Intracranial control also notably strong. Could this combo help overcome resistance in more aggressive ALK variants? #research #lungcancer

💡Final #CHRYSALIS trials results: #Amivantamab delivers durable responses in #METex14 #NSCLC, even after MET TKI failure. Overall population: - ORR 32% - CBR 69% - median DoR 11.2 mo 48% asian, 39% white. 9% discontinued due to side effects @oncoalert.bsky.social

📰EGFR-TKI resistance in LUAD isn’t always genetic. - 39 pts-derived organoids - 50% resistant organoids had no know res mutations. A “basal-shift” phenotype drives res via NKX2-1 loss. - Knockout of NKX2-1 → basal-shift + Osim res - These tumors often lose CDKN2A/B pbs.twimg.com/media/Gq6QwX...

Very honored of this important recognition in my born country. Blessed to share this special moment with my family, friends and great colleagues from Argentina 🇦🇷 looking forward to continue working with @UBAonline from OSU @OhioStateMedOnc ! Thanks to all my team @rolfolab.bsky.social

🔬📈 Check out our new commentary on Selinexor (an XPO1 inhibitor) + ICIs in uveal melanoma patients in a phase  1B trial! ➡️12m OS 55 %  ➡️0 % ORR ➡️manageable safety profile @christianrolfo.bsky.social @rolfolab.bsky.social @oncoalert.bsky.social #CarlosAyala pmc.ncbi.nlm.nih.gov/articles/PMC...

Selinexor in Uveal Melanoma: A Hopeful Step or Just Another Hurdle?

pmc.ncbi.nlm.nih.gov

New research from the #VISION trial of #tepotinib in #NSCLC with #METex14 skipping highlights key differences when patients are identified by LBxvs TBx. ➡️ #Tepotinib showed robust efficacy regardless of biopsy type @christianrolfo.bsky.social @oncoalert.bsky.social

Visit at #AACR25 the poster by Dr. Eswar Shankar on “Synergistic Inhibition of TNBC via EZH2 inhibition and D1 Receptor Agonism” @OSUCCC_James @osuwexmed.bsky.social @christianrolfo.bsky.social @theaacr.bsky.social pbs.twimg.com/media/Gpay9i...

Super excited to share the review I wrote with Carolina Reduzzi published in the Journal of Liquid Biopsy on the transformative impact of LB in oncology! 🩸🔬 LB is reshaping cancer care 💥 Check it out 👉 pubmed.ncbi.nlm.nih.gov/40255897/ @islb.info @christianrolfo.bsky.social @rolfolab.bsky.social

Congrats Roberto! And welcome to @rolfolab.bsky.social !!!

Roberto Borea MD@robertoboreamd.bsky.social · last yr.

Honored to be here at hashtag #TexasLung25 in #Austin as one of the 10 winners of the poster competition 🏅 Grateful for the chance to meet with exceptional people 👐 @stephenvliu.bsky.social @tinacascone @christianrolfo.bsky.social

Day 3 at #TexasLung25 diving into diagnostics, #MRD, and #LiquidBiopsy with an outstanding faculty! 🩸🔬 Learning from the best: @christianrolfo.bsky.social @davidgandera @WadeIams @osucccjames.bsky.social @rolfolab.bsky.social Exciting discussions shaping the future of #lungcancer testing! 📚

Honored to be here at hashtag #TexasLung25 in #Austin as one of the 10 winners of the poster competition 🏅 Grateful for the chance to meet with exceptional people 👐 @stephenvliu.bsky.social @tinacascone @christianrolfo.bsky.social

As always, an insightful presentation by @UmbertoMalapelle ➡️ "From single gene testing to CGP." 🔬✨ at #ELCC25 @myesmo.bsky.social We must continue this path to improve treatment selection! @islb.info #precisiononcology #lungcancer ⬇️ Key message

Today, I had the pleasure of presenting to the @MtSinaiASCOOSIG on the role of #liquidbiopsy in clinical practice and #precisiononcology! ❤️ An incredibly dynamic and engaging group! Great discussions and insights! @osucccjames.bsky.social @rolfolab.bsky.social @christianrolfo.bsky.social @unige

📢 5-year outcomes from EMPOWER-Lung 1: 1L cemiplimab vs chemo in PD-L1 high (≥50%) NSCLC! 👫🏻 565 pts; 1 vs 1 ✅ mOS favors cemiplimab: 26.1 vs 13.3m (HR 0.59), 38.8m in PD-L1 ≥90% ✅ PFS 8.1 vs 5.3m (HR 0.50) ✅ 5y OS rate: 29% vs 15% www.jto.org/article/S155... #Immunotherapy #NSCLC

What a great news! Finally we have a journal dedicated to liquid biopsy research! I am truly excited. 🔥

International Society of Liquid Biopsy@islb.info · last yr.

🎉🩸 Thrilled to share that the Journal of Liquid Biopsy is now officially live in PubMed and PMC! A significant step forward for JLB Check it out here: pmc.ncbi.nlm.nih.gov/journals/?te... #LiquidBiopsy #PubMed @christianrolfo.bsky.social @yukselurun.bsky.social @eloisajantus.bsky.social

📢 Exciting update in the field of liquid biopsy! A new editorial highlights the essential role of the International Society of Liquid Biopsy (ISLB) in establishing quality framework for LB clinical implementation. 🧬🩸 Read more: doi.org/10.1016/j.crit… #LiquidBiopsy @christianrolfo.bsky.social

🚨 Out in @natrevclinoncol.bsky.social 📌ctDNA helps uncover resistance mechanisms 📌Standardized protocols are crucial for improving applications 📌ctDNA + tissue provides a more comprehensive view nature.com/articles/s41... @christianrolfo.bsky.social @osucccjames.bsky.social

Now you can find the link to complete our @islb.info survey in the @oncoalert.bsky.social newsletter! 📨 It only takes 5 min to help us understand how LB 🩸 is reshaping clinical practice worldwide! bit.ly/43JzN03 @christianrolfo.bsky.social @rolfolab.bsky.social @weoncologists.bsky.social

Diving into the latest on #METex14 skipping #NSCLC, from testing to treatment, with an outstanding panel of experts! 🌟🔬 --> bit.ly/3DFSzLi Panelists: @christianrolfo.bsky.social #UmbertoMalapelle #YasushiYatabe #MervatMahrous Organizer: #touchOncology @rolfolab.bsky.social @oncoalert.bsky.social

Honored to be among the winners of the #TexasLung25 Poster Competition! 🎉 Grateful for the opportunity to share my research and contribute to the future of #lungcancer! @christianrolfo.bsky.social @rolfolab.bsky.social @stephenvliu.bsky.social @osucccjames.bsky.social ➡️ hubs.la/Q03bqnlB0

The HER2 protein is becoming a crucial target not only in breast cancer but also in other tumor subtypes. 🔬✨ Super experts discuss the role of IHC in #lungcancer and #ovariancancer! @christianrolfo.bsky.social @rolfolab.bsky.social @osucccjames.bsky.social #HER2 #IHC #Targettherapy

The OncoAlert Network 🚨@oncoalert.bsky.social · last yr.

JOIN US for a discussion on HER2🧬testing & evolving role of IHC🔬 in hashtag#LungCancer & hashtag#OvarianCancer REGISTER HERE👇👇 buff.ly/7F6ztd4 JOIN US TUESDAY MARCH 11, 2025

✨ Insightful presentation by @manelesteller.bsky.social from @carrerasijc.bsky.social at @osuwexmed.bsky.social Starting from #epigenetics to #spatialtranscriptomics, unlocking a deeper understanding of tumor biology and cancer treatment! 🔬🧬💊 @christianrolfo.bsky.social @rolfolab.bsky.social

⏱️ To-do list for today: Tune in to the live webinar by @iaslc.bsky.social covering key highlights from the 2024 Hot Topic in Basic & Translational Science Conference! 🔬🧬 Don't miss out on the latest breakthroughs! @christianrolfo.bsky.social @rolfolab.bsky.social www.iaslc.org/meetings-web...

2024 Hot Topic in Basic & Translational Science Conference Highlights | IASLC

IASLC presents a one-hour, live session focused on key highlights from the 2024 Hot Topic in Basic & Translational Science Conference. This webinar will ser ...

iaslc.org

Don't miss the chance to dive into this interesting discussion on lung cancer with an incredible faculty! 🔎🫁💊 #lungcancer #myESMO #DeepDiveLungCancer @christianrolfo.bsky.social @rolfolab.bsky.social ow.ly/vbSt50UPrrS

🚨 Share your expertise in the liquid biopsy field! 🌟 Participate in the #ISLB survey to help shape strategies for improving #liquidbiopsies in clinical oncology. Let’s advance precision care for medical oncologists together! 🩺🔬 @christianrolfo.bsky.social @rolfolab.bsky.social

The OncoAlert Network 🚨@oncoalert.bsky.social · 2y ago

Survey Participation Request on Behalf of @isliquidbiopsy & @OncoAlert Oncologist Attitudes and Practices on Liquid Biopsy 👉 https://buff.ly/3Cvf8BJ This survey aims to evaluate oncologists' attitudes, practices, and barriers to the use of liquid biopsy in clinical care.

When tissue is the issue! Great presentation by @christianrolfo.bsky.social at the XIII Molecular Cytopathology We need to use liquid biopsy 🩸 and tissue together to get as many informations as possible! 🧬 @ohiostateuniversity @rolfolab.bsky.social @UmbertoMalapel1 @MariantoniaNac1

A great initiative by European School of Oncology to share clinical cases among oncologists! I had the possibility to discuss a geriatric breast cancer patients and how to handle specific “frail” situations! 👵🏻 Check the link! 🎯 bit.ly/e-ESO @unige